Replimune Group, Inc. (NASDAQ:REPL) Receives Consensus Rating of “Moderate Buy” from Brokerages

Replimune Group, Inc. (NASDAQ:REPL) has received an average recommendation of “Moderate Buy” from the eleven analysts that are currently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation, six have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year target price among analysts that have issued a report on the stock in the last year is $9.75.

Several equities research analysts recently issued reports on REPL shares. Leerink Partners raised shares of Replimune Group from a “market perform” rating to an “outperform” rating and raised their target price for the stock from $3.00 to $13.00 in a research report on Monday, October 20th. Piper Sandler upgraded shares of Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price target on the stock in a report on Monday, October 20th. JPMorgan Chase & Co. raised shares of Replimune Group from an “underweight” rating to a “neutral” rating and set a $11.00 price objective for the company in a research note on Monday, October 20th. HC Wainwright upgraded Replimune Group from a “neutral” rating to a “buy” rating and set a $12.00 price objective for the company in a report on Monday, October 27th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Replimune Group in a report on Monday, December 29th.

Insider Transactions at Replimune Group

In other Replimune Group news, Director Kapil Dhingra sold 3,169 shares of the business’s stock in a transaction that occurred on Tuesday, December 9th. The shares were sold at an average price of $10.40, for a total transaction of $32,957.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Sushil Patel sold 10,000 shares of the stock in a transaction on Tuesday, December 2nd. The stock was sold at an average price of $11.13, for a total transaction of $111,300.00. Following the completion of the sale, the chief executive officer directly owned 333,576 shares of the company’s stock, valued at $3,712,700.88. The trade was a 2.91% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last quarter, insiders sold 25,625 shares of company stock valued at $257,607. 5.20% of the stock is currently owned by company insiders.

Institutional Trading of Replimune Group

A number of institutional investors have recently added to or reduced their stakes in the business. Readystate Asset Management LP raised its holdings in shares of Replimune Group by 1,296.2% during the 3rd quarter. Readystate Asset Management LP now owns 2,621,012 shares of the company’s stock valued at $10,982,000 after buying an additional 2,433,292 shares during the period. Braidwell LP raised its stake in shares of Replimune Group by 550.3% during the third quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock valued at $11,523,000 after purchasing an additional 2,327,205 shares during the period. Balyasny Asset Management L.P. lifted its position in shares of Replimune Group by 507.4% during the third quarter. Balyasny Asset Management L.P. now owns 2,628,100 shares of the company’s stock worth $11,012,000 after purchasing an additional 2,195,448 shares in the last quarter. Erste Asset Management GmbH boosted its stake in shares of Replimune Group by 13,597.5% in the third quarter. Erste Asset Management GmbH now owns 1,630,000 shares of the company’s stock valued at $7,074,000 after purchasing an additional 1,618,100 shares during the period. Finally, UBS Group AG boosted its stake in shares of Replimune Group by 270.4% in the third quarter. UBS Group AG now owns 901,630 shares of the company’s stock valued at $3,778,000 after purchasing an additional 658,233 shares during the period. 92.53% of the stock is owned by hedge funds and other institutional investors.

Replimune Group Price Performance

REPL stock opened at $8.03 on Friday. The stock has a market capitalization of $629.87 million, a price-to-earnings ratio of -2.32 and a beta of 0.72. The company has a quick ratio of 6.31, a current ratio of 6.31 and a debt-to-equity ratio of 0.26. Replimune Group has a 52-week low of $2.68 and a 52-week high of $14.80. The stock’s fifty day simple moving average is $9.46 and its 200-day simple moving average is $7.60.

Replimune Group (NASDAQ:REPL) last released its earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.87) by ($0.03). Equities research analysts expect that Replimune Group will post -2.97 EPS for the current year.

About Replimune Group

Replimune Group, Inc is a clinical‐stage biotechnology company focused on developing next‐generation oncolytic immunotherapies for the treatment of solid tumors. The company’s proprietary “RP” platform leverages genetically engineered herpes simplex virus type 1 (HSV-1) vectors armed with immunomodulatory payloads to selectively infect, replicate within and destroy cancer cells, while also stimulating systemic antitumor immune responses.

Replimune’s lead candidate, RP1, incorporates GM-CSF and a fusogenic protein to enhance both direct oncolysis and immune activation.